Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer
3d agoen
From the article
Conditions : Metastatic Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8 Interventions : Procedure: Biospecimen Collection; Procedure: Computed Tomography; Other: Gallium Ga 68 Gozetotide; Drug: Lutetium Lu 177 Vipivotide Tetraxetan; Device: Positron Emission Tomography; Other: Questionnaire Administration; Device: Single Photon Emission Computed Tomography; Other: Technetium Tc-99m Sulfur Colloid Sponsors : University of Michigan Rogel Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
GE HealthCare and Mayo Clinic launch theranostics study to personalize prostate cancer treatment
GE HealthCare and Mayo Clinic have launched the MI-BET research collaboration, a theranostics study aimed at developing a more personalized
mayocl.in·15h ago
Phase 3 trial: PSMA-PET-CT may help some high-risk men avoid prostate biopsy
A phase 3 clinical trial published in The Lancet Oncology suggests that PSMA-PET-CT imaging may help determine which men at high clinical ri
mdsc.pe·8d ago
Phase I CARLYSLE study: CAR T-cell therapy obe-cel shows favorable safety and clinical benefit in severe refractory lupus
This article reports initial results from the phase I CARLYSLE study evaluating obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-ce
lupus.bmj.com·26d agoAnixa Biosciences Aktie: Höchste Lira-cel-Dosis erreicht
aktiencheck.de
La creatina no solo desarrolla músculo: un estudio revela su potencial para fortalecer la inmunoterapia contra el cáncer
Infobae·10h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.